7.84 -0.20 (-2.52%)
ENZN
Stock Details
Last Trade:7.84 Change:-0.20 (-2.52%) Prev Close:8.04 Open: 7.93 Days Range:7.79 – 8.06 52 Week Range: 2.95 - 9.48 Volume:187206 P/E: 392.00EPS:0.02
View AllRecent Alerts 07/04/09
Recent Alert on 06/22/09 at 4:01pm
Enzon Pharma (ENZN) Opens Phase II Trial for PEG-SN38
Enzon Pharma (ENZN) Opens Phase II Trial for PEG-SN38
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients... Read More
Recent Alert on 06/01/09 at 9:56am
Enzon (ENZN) Reports Positive Preliminary Data in Company’s HIF-1 Alpha Phase 1 Study Evaluating EZN-2968 in Patients With Solid Tumors
Enzon (ENZN) Reports Positive Preliminary Data in Company’s HIF-1 Alpha Phase 1 Study Evaluating EZN-2968 in Patients With Solid Tumors
Recent Alert on 05/15/09 at 8:32am
Enzon Pharmaceuticals (ENZN) Trading Up In Pre-Market After FDA Approved Its Drug For Rheumatoid Arthritis
Enzon Pharmaceuticals (ENZN) Trading Up In Pre-Market After FDA Approved Its Drug For Rheumatoid Arthritis
Recent Alert on 05/15/09 at 8:32am
Enzon Pharmaceuticals (ENZN) Trading Up In Pre-Market After FDA Approved Its Drug For Rheumatoid Arthritis
Enzon Pharmaceuticals (ENZN) Trading Up In Pre-Market After FDA Approved Its Drug For Rheumatoid Arthritis
Recent Alert on 05/15/09 at 8:32am
Enzon Pharmaceuticals (ENZN) Trading Up In Pre-Market After FDA Approved Its Drug For Rheumatoid Arthritis
Enzon Pharmaceuticals (ENZN) Trading Up In Pre-Market After FDA Approved Its Drug For Rheumatoid Arthritis
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 05/21/08 at 6:29am
Enzon Shareholder Demands Possible Sale of Commercial Operations Be Explored
Enzon Shareholder Demands Possible Sale of Commercial Operations Be Explored